Aortic Replacement Using Individualised Regenerative Allografts - ARISE (the "Surveillance")

NCT ID: NCT02527629

Last Updated: 2020-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

144 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-30

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of decellularized human heart valves for aortic heart valve replacement in comparison to current valve substitutes.

Safety endpoints include cardiovascular adverse events, time to re-operation, re-intervention and explantation.

Efficacy endpoints include freedom from valve dysfunction and hemodynamic performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, non-randomized, single-arm, multi-centre surveillance study to be conducted in Europe.

The Surveillance is designed as a study, where

* ARISE AV is prescribed in the usual manner in accordance with the terms of the approval.
* Assignment of the patient to a particular therapeutic strategy is not decided in advance by this Surveillance Protocol but falls within current practice and the prescription of ARISE AV is clearly separated from the decision to include the patient in the Surveillance.
* No additional diagnostic or monitoring procedures shall be applied to the patients.
* and epidemiological methods shall be used for the analysis of collected data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Valve Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Decellularized human valves

Aortic heart valve replacement

Decellularized human heart valves

Intervention Type OTHER

Decellularized human aortic heart valves

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Decellularized human heart valves

Decellularized human aortic heart valves

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Arise Aortic Valve (AV)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

i. Indication for aortic valve replacement according to current medical guidelines in valvular heart disease

ii. Informed consent of legal guardians or patients, assent of patients

Exclusion Criteria

i. The patient has not provided Surveillance informed consent.

ii. The patient shall not suffer from:

* generalized connective tissue disorders (eg, Marfan syndrome), or .
* active rheumatic disorders, or
* severe asymmetric calcification of the valve ring.

iii. The coronary arteries of the patient shall not be in abnormal position or heavily calcified.

iv. Patients shall not show hypersensitivity against sodium dodecyl sulphate (SDS), sodium desoxycholate (SDC), human collagen (or other elastic fibers) or Benzonase®.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hannover Medical School

OTHER

Sponsor Role collaborator

Leiden University Medical Center

OTHER

Sponsor Role collaborator

Azienda Ospedaliera di Padova

OTHER

Sponsor Role collaborator

Hospital Clinic of Barcelona

OTHER

Sponsor Role collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

Sponsor Role collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role collaborator

Heinrich-Heine University, Duesseldorf

OTHER

Sponsor Role collaborator

Vienna General Hospital

OTHER

Sponsor Role collaborator

corlife

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Axel Haverich, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Hannover Medical School

Samir Sarikouch, PD Dr.

Role: STUDY_DIRECTOR

Hannover Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitair Ziekenhuis Leuven, UZL

Leuven, , Belgium

Site Status

University of Düsseldorf, Department of Cardiovascular Surgery

Düsseldorf, , Germany

Site Status

Hannover Medical School

Hanover, , Germany

Site Status

Azienda Ospedaliera di Padova, U.O.C. di Cardiochirurgia Pediatrica e Cardiopatie Congenite

Padua, , Italy

Site Status

Leids Universitair Medisch Centrum, LUMC

Leiden, , Netherlands

Site Status

University Hospital Clinic de Barcelona, Cardiovascular Surgery administrative area

Barcelona, , Spain

Site Status

Kinderspital Zürich

Zurich, , Switzerland

Site Status

Royal Brompton and Harefield National Health Service Trust

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Italy Netherlands Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Horke A, Tudorache I, Laufer G, Andreas M, Pomar JL, Pereda D, Quintana E, Sitges M, Meyns B, Rega F, Hazekamp M, Hubler M, Schmiady M, Pepper J, Rosendahl U, Lichtenberg A, Akhyari P, Jashari R, Boethig D, Bobylev D, Avsar M, Cebotari S, Haverich A, Sarikouch S. Early results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement: the ARISE study and ARISE Registry data. Eur J Cardiothorac Surg. 2020 Nov 1;58(5):1045-1053. doi: 10.1093/ejcts/ezaa100.

Reference Type RESULT
PMID: 32386409 (View on PubMed)

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Study results

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Grant Agreement No: 643597

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2015- 01, 20.07.2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.